ALPS Advisors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

ALPS Advisors’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-93,978	Closed	-$1.05M	–	909
2017 Q3	$1.05M	Sell	93,978 -3,390	-3%	-$37.4K	0.01%	237
2017 Q2	$1.07M	Buy	97,368 +2,542	+3%	+$25.4K	0.01%	225
2017 Q1	$929K	Buy	94,826 +4,720	+5%	+$47.1K	0.01%	224
2016 Q4	$973K	Sell	90,106 -14,211	-14%	-$142K	0.01%	220
2016 Q3	$1.07M	Sell	104,317 -9,384	-8%	-$102K	0.01%	220
2016 Q2	$1.49M	Buy	113,701 +11,379	+11%	+$149K	0.01%	190
2016 Q1	$1.13M	Buy	102,322 +35,240	+53%	+$313K	0.01%	183
2015 Q4	$617K	Sell	67,082 -10,555	-14%	-$88.4K	0.01%	259
2015 Q3	$5.39K	Buy	77,637 +28,414	+58%	+$243K	0.01%	279
2015 Q2	$483K	Buy	49,223 +24,027	+95%	+$219K	﹤0.01%	546
2015 Q1	$223K	Buy	+25,196	New	+$201K	﹤0.01%	641

ALPS Advisors's SCLN Position: Q4 2017 in Review

ALPS Advisors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 93,978 shares — an estimated $1.05M sold.

ALPS Advisors first reported a position in SCLN in Q1 2015 and held it in 11 quarters. The position peaked at $1.49M in Q2 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

ALPS Advisors reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
ALPS Advisors sold 93,978 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.05M.
ALPS Advisors first reported a position in Sciclone Pharmaceuticals Inc in Q1 2015 and held it in 11 quarters.
ALPS Advisors's Sciclone Pharmaceuticals Inc position peaked at $1.49M in Q2 2016.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on ALPS Advisors's 13F filing for Q4 2017, filed 5 Feb 2018.